Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 259-264

  Ito, Yasuhiro ^a   Karayama, Masato ^a   Inui, Naoki ^a   Kuroishi, Shigeki ^b   Nakano, Hideki ^c   Nakamura, Yutaro ^a   Yokomura, Koshi ^d   Toyoshima, Mikio ^e   Shirai, Toshihiro ^f   Masuda, Masafumi ^g   Yamada, Takashi ^g   Yasuda, Kazumasa ^h   Hayakawa, Hiroshi ⁱ   Suda, Takafumi ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ensyu Hospital   (Japan)

^c Department of Pathology   (Japan)

^d SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^e HAMAMATSU ROSAI HOSPITAL   (Japan)

^f SHIZUOKA GENERAL HOSPITAL   (Japan)

^g SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

^h Iwata City Hospital   (Japan)

ⁱ National Hospital Organization   (Japan)

Author keywords

Antiemetic; Aprepitant; Carboplatin; Chemotherapy induced nausea and vomiting; Non small cell lung cancer; Pemetrexed

Indexed keywords

APREPITANT; BEVACIZUMAB; CARBOPLATIN; DEXAMETHASONE; PACLITAXEL; PEMETREXED; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; MORPHOLINE DERIVATIVE; SEROTONIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HICCUP; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; LUNG NEOPLASMS; MIDDLE AGED; NAUSEA; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; SEROTONIN; VOMITING;

EID: 84901937418     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.017     Document Type: Article

References (26)

1. Reck M., Heigener D.F., Mok T., Soria J.C., Rabe K.F. Management of non-small-cell lung cancer: recent developments. Lancet 2013, 382:709-719.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
4. Roscoe J.A., Morrow G.R., Hickok J.T., Stern R.M. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000, 20:113-121.
5. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358:2482-2494.
6. Roila F., Herrstedt J., Aapro M., Gralla R.J., Einhorn L.H., Ballatori E., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21 Suppl 5:v232-v243.
7. Griffin A.M., Butow P.N., Coates A.S., Childs A.M., Ellis P.M., Dunn S.M., et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996, 7:189-195.
8. Molassiotis A., Stricker C.T., Eaby B., Velders L., Coventry P.A. Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care (Engl) 2008, 17:444-453.
9. Bloechl-Daum B., Deuson R.R., Mavros P., Hansen M., Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006, 24:4472-4478.
10. Osoba D., Zee B., Warr D., Kaizer L., Latreille J., Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology 1996, 53(Suppl 1):92-95.
11. Roscoe J.A., Morrow G.R., Aapro M.S., Molassiotis A., Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2011, 19:1533-1538.
12. Basch E., Prestrud A.A., Hesketh P.J., Kris M.G., Feyer P.C., Somerfield M.R., et al. Antiemetics American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29:4189-4198.
13. Ettinger D.S., Armstrong D.K., Barbour S., Berger M.J., Bierman P.J., Bradbury B., et al. J Natl Compr Canc Netw 2012, 10:456-485.
14. Grunberg S.M., Deuson R.R., Mavros P., Geling O., Hansen M., Cruciani G., et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004, 100:2261-2268.
15. Warr D.G., Hesketh P.J., Gralla R.J., Muss H.B., Herrstedt J., Eisenberg P.D., et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005, 23:2822-2830.
16. Rapoport B.L., Jordan K., Boice J.A., Taylor A., Brown C., Hardwick J.S., et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010, 18:423-431.
17. Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., Julie Ma.G., Eldridge K., Hipple A., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003, 97:3090-3098.
18. Hesketh P.J., Grunberg S.M., Gralla R.J., Warr D.G., Roila F., de Wit R., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003, 21:4112-4119.
19. Schmoll H.J., Aapro M.S., Poli-Bigelli S., Kim H.K., Park K., Jordan K., et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006, 17:1000-1006.
20. Waqar M.A., Chitneni P., Williams K., Goodgame B.W., Gao F., Govindan R., et al. A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin containing regimens for treatment of cancer without prophylactic aprepitant. J Clin Oncol 2008, 26 S:20626.
21. Saito M., Aogi K., Sekine I., Yoshizawa H., Yanagita Y., Sakai H., et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009, 10:115-124.
22. Celio L., Frustaci S., Denaro A., Buonadonna A., Ardizzoia A., Piazza E., et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011, 19:1217-1225.
23. Olver I.N. Antiemetic study methodology: recommendations for future studies. Oncology 1996, 53(Suppl 1):96-101.
24. Tanioka M., Kitao A., Matsumoto K., Shibata N., Yamaguchi S., Fujiwara K., et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013, 109:859-865.
25. Feyer P., Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2010, 22:30-38.
26. Vardy J., Chiew K.S., Galica J., Pond G.R., Tannock I.F. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006, 94:1011-1015.